Search
 

Ulcerative Colitis Clinical Trials

Browse current & upcoming clinical research / studies on Ulcerative Colitis. There are a total of 278 clinical trials for Ulcerative Colitis in 50 countries with 34 trials currently in the United States. 71 are either active and/or recruiting patients or have not yet been completed. Click the title of each study to get the complete details on eligibility, location & other facts about the study.

Other clinical trials

Definitions
Interventional trials
Determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
Observational trials
Address health issues in large groups of people or populations in natural settings.
Recruiting
Participants are currently being recruited and enrolled.
Active, not recruiting
Study is ongoing (i.e., patients are being treated or examined), but enrollment has completed.
Not yet recruiting
Participants are not yet being recruited or enrolled.
Enrolling by invitation
Participants are being (or will be) selected from a predetermined population.
Completed
The study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred).
Withdrawn
Study halted prematurely, prior to enrollment of first participant.
Suspended
Recruiting or enrolling participants has halted prematurely but potentially will resume.
Terminated
Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.
January 2015 - September 2017
Background: Curcumin in an active phytochemical substance, used as part of the human diet, that has anti-inflammatory and anti-oxidative properties which were demonstrated in multiple experimental models of colitis including a positive effect on maintenance of remission in adult ulcerative colitis (UC) patients. Objectives: To examine the effect of curcumin as complementary medication in induction and maintenance therapy in pediatric patients with mild to moderate ulcerative colitis. Design: A prospective, randomized, placebo-controlled study. Setting: Pediatric gastroenterology centers. Participants: Children 6 year to 18 years who are diagnosed with mild to moderate UC and are planned to receive either 5-ASA or corticosteroids induction treatment. Main outcome measures: Disease activity defined by the Pediatric Ulcerative Colitis Activity Index (PUCAI) at 2 weeks and 6 months. Secondary outcome measures: Effect of curcumin treatment on serum inflammatory markers, calprotectin and fecal microbiota. Data analysis: Data will be collected and analyzed using SPSS (version 21.0, SPSS, Inc., Chicago, IL, USA). Fisher's exact test will be used to explore univariate associations between primary outcomes and categorical variables. Associations of continues variables with primary outcome measures will be examined using ANOVA with repeated measures. P-values <0.05 will be considered significant.
Sponsor: Schneider Children's Medical Center, Israel
Study type: Interventional
January 2015 - January 2017
For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.
Sponsor: Ferring Pharmaceuticals
Study type: Observational
December 2014 - February 2017
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active Ulcerative Colitis (UC).
Sponsor: Celgene Corporation
Study type: Interventional
November 2014 - November 2017
This Phase III, double blind, placebo and active comparator controlled, multicen ter study will investigate the efficacy and safety of etrolizumab in induction o f remission in patients with moderately to severely active ulcerative colitis (U C) who are naïve to TNF inhibitors and refractory to or intolerant of prior immu nosuppressant and/or corticosteroid treatment.
Sponsor: Hoffmann-La Roche
Study type: Interventional
October 2014 - December 2018
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)
Sponsor: Dr. Falk Pharma GmbH
Study type: Interventional
October 2014 - March 2015
The purpose of this study is to determine if aerobic exercise training can serve as comprehensive palliative care, whereby enhancing cardiovascular fitness, mitigating depressive symptoms and augmenting sleep while bolstering health related quality of life in youth with Crohn's Disease and Ulcerative Colitis.
Sponsor: University of Basel
Study type: Interventional
September 2014 - November 2017
This Phase III, double blind, placebo and active comparator controlled, multicen ter study will investigate the efficacy and safety of etrolizumab in induction o f remission in patients with moderately to severely active ulcerative colitis (U C) who are naïve to TNF inhibitors and refractory to or intolerant of prior immu nosuppressant and/or corticosteroid treatment.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - January 2019
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parall el-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating patients with moderate to severe ulcerativ e colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Patients will be randomized in a 1:1 ratio to receive either etrolizumab (105 mg by subc utaneous injection [SC] every 4 weeks [Q4W]) + placebo (intravenous [IV] infusio n at Weeks 0, 2, and 6, then every 8 weeks) or infliximab (5 mg/kg IV at Weeks 0 , 2, and 6, then every 8 weeks) + placebo (SC Q4W). Time on treatment is 54 week s.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - November 2021
This two-part, open-label extension (OLE) and safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate t o severe ulcerative colitis (UC) patients previously enrolled in etrolizumab Pha se III studies.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - January 2017
The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.
Sponsor: Children's Hospital Boston
Study type: Interventional
Page  
Home  •  Browse by Condition  •  Search Clinical Trials
The information found on this site has been provided by clinicaltrials.gov in accordance with their terms & conditions. Neither we (inclinicaltrials.com), the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.